局限性前列腺癌两次立体定向消融放疗(2STAR):一项前瞻性临床试验结果
2STAR是一项II期前瞻性临床试验,纳入30例低危或中危前列腺癌患者,接受26 Gy分2次每周照射的SABR(EQD2 110 Gy1.4),中位随访49.3个月。主要终点为EPIC生活质量,结果显示生活质量改变轻微、晚期3-4级毒性低,生化控制率在多数为不良中危患者中令人鼓舞,但需更长随访。
要点
- 30例低/中危前列腺癌接受26 Gy/2次每周SABR,中位随访49.3个月。
- 6例(20.7%)泌尿域、6例(21.4%)肠道域、3例(20%)性功能域出现EPIC MCIC。
- 1例生化失败并观察中,晚期3-4级毒性低,生活质量改变轻微。
核心结论
- 两次SABR治疗前列腺癌安全可行,生活质量改变轻微且晚期3-4级毒性率低;鉴于多数为不良中危疾病,PSA动力学和生化控制率令人鼓舞,但需要更长随访。
研究设计与样本
- II期前瞻性临床试验,纳入30例低危或中危前列腺癌患者,植入3枚金标记用于图像引导,CTV仅包括前列腺,PTV通过直肠固定装置外扩3 mm,处方剂量26 Gy分2次每周照射(EQD2 110 Gy1.4),主要终点为EPIC生活质量,MCIC定义为EPIC QOL下降>0.5 SD。
主要发现
- 30例患者中10%低危、33%有利中危、57%不利中危,5例接受短程ADT,中位nPSA为0.2 ng/ml,1例生化失败并观察中,56.6%患者有4年PSA无复发生存。
- 6例(20.7%)患者泌尿域出现MCIC,6例(21.4%)肠道域出现MCIC,3例(20%)性功能域出现MCIC。
关键数值与推荐
- MCIC定义为EPIC QOL下降>0.5 SD;处方剂量26 Gy分2次每周照射(EQD2 110 Gy1.4);中位随访49.3个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要更长随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Ultrahypofractionation is appealing for prostate cancer (PCa) due to low α/β, and increasing the dose per fraction could improve the therapeutic index. Here we report the outcomes of a phase II prostate SABR trial using two fractions. METHODS: Patients had low or intermediate risk prostate cancer. Three gold fiducials were implanted for image guidance. The clinical target volume (CTV) included the prostate only, and the planning target volume (PTV) was a 3 mm expansion enabled through the use of a rectal immobilization device. The dose prescribed was 26 Gy in 2 weekly fractions (EQD2 110 Gy1.4). The primary endpoint was quality of life using EPIC, and minimal clinically important change (MCIC) was defined as an EPIC QOL decrease >0.5 SD. RESULTS: 30 patients were accrued with a median follow-up of 49.3 months. 10% had low-risk, 33% had favourable intermediate-risk and 57% had unfavourable intermediate-risk PCa. Five patients received a short course of ADT. Median nPSA was 0.2 ng/ml. One patient had BF and is being observed. 56.6% of patients had a 4yPSARR. Six (20.7%) patients had a MCIC in the urinary domain, 6 (21.4%) had a MCIC in the bowel domain, and 3 (20%) had a MCIC in the sexual domain. CONCLUSIONS: Two-fraction SABR in prostate cancer is safe and feasible, with a minimal change in QOL and a low rate of late grade 3-4 toxicity. The PSA kinetics and biochemical control rates are encouraging given that the majority had unfavourable intermediate-risk disease, although longer follow-up is required.
引用
- Alayed Y, Cheung P, Chu W, et al. Two StereoTactic ablative radiotherapy treatments for localized prostate cancer (2STAR): Results from a prospective clinical trial. Radiother Oncol. 2019. PMID: 31015175. doi:10.1016/j.radonc.2019.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。